EASL Podcasts European Association for the Study of the Liver

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.
Faculty
Marta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episode
EASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.All EASL Studio Podcasts are available on EASL Campus.

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.
Faculty
Bruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.
Related episodes
EASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?All EASL Studio Podcasts are available on EASL Campus.

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.
Faculty
Debbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper (Faculty)This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
Related episodes
EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinEASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?All EASL Studio Podcasts are available on EASL Campus.

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.
Faculty
Patrizia Burra (Moderator)Maria Buti (Faculty)Peter Jepsen (Faculty)Shira Zelber-Sagi (Faculty)Related episodes
EASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policyEASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S2E2: Fats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.
Faculty
Aleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodes
EASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challengesEASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challengesThis episode is scheduled in honour of the Rare Disease Day (29 February).
All EASL Studio Podcasts are available on EASL Campus.

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?
Faculty
Paolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodes
EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureEASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?All EASL Studio Podcasts are available on EASL Campus.